HealthCap VIII Advisor AB

Investment decisions at HealthCap are made by a team of three managing partners: Staffan Strömsten, Mikael Salazar, and Patrik Sobocki. They co-lead deal sourcing, due diligence, and portfolio oversight from the Stockholm office. The firm operates with a lean team of around 15 professionals (public record).

HealthCap invests across the lifecycle, from seed-stage startups to growth-stage private companies, and also holds public equity positions in later-stage life-science firms. This hybrid approach allows the firm to deploy capital in both private and public markets within its healthcare mandate (public record).

HealthCap primarily invests in the Nordic region (Sweden, Denmark, Norway, Finland) and the United States. The firm's Nordic roots give it unique access to university spinouts and early-stage biotech clusters, while its US activity covers later-stage and cross-border deals (public record).

HealthCap focuses exclusively on life sciences, including therapeutics (oncology, neurology, rare diseases), diagnostics, medical devices, and biotech tools. The firm explicitly avoids healthcare services, digital health platforms that are not drug- or device-related, and non-healthcare sectors (public record).

HealthCap sources deals through its network of Nordic academic institutions, scientific advisory boards, and existing portfolio company referrals. The firm's managing partners maintain relationships with key researchers and entrepreneurs in the life sciences, giving it proprietary access to early-stage opportunities before they reach broader syndication (public record).

No, HealthCap is structured as a specialist venture and growth equity asset manager raising capital from institutional investors, pension funds, and family offices. It operates through a series of closed-end funds (HealthCap I through VIII) and is not a single-family or multi-family office (public record).

HealthCap has raised eight funds since 1996, deploying over €1B in cumulative capital across more than 100 life-science companies. The firm's previous funds have generated returns through IPOs, trade sales, and secondary sales, though specific fund-level performance figures are not publicly disclosed (public record).